2024 |
Exide Industries Ltd.
|
Independent Director |
66.8 L |
65.8 % |
2024 |
Piramal Pharma Ltd.
|
Independent Director |
42 L |
12.0 % |
2024 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
2.6 L |
-35.0 % |
2023 |
Exide Industries Ltd.
|
Independent Director |
40.3 L |
- |
2023 |
Piramal Pharma Ltd.
|
Independent Director |
37.5 L |
- |
2023 |
Alivus Life Sciences Ltd.
|
Independent Non Exe. Director |
18 L |
- |
2023 |
Glenmark Pharmaceuticals Ltd.
|
Independent Non Exe. Director |
15 L |
- |
2023 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
4 L |
0.0 % |
2022 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
4 L |
-11.1 % |
2022 |
Exide Industries Ltd.
|
Addtnl Independent Director |
- |
- |
2022 |
Alivus Life Sciences Ltd.
|
Independent Director |
- |
- |
2022 |
Glenmark Pharmaceuticals Ltd.
|
Non-Exec. & Independent Dir. |
- |
- |
2021 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
4.5 L |
0.0 % |
2021 |
Glenmark Pharmaceuticals Ltd.
|
Non-Exec. & Independent Dir. |
- |
- |
2021 |
Exide Industries Ltd.
|
Additional Director |
- |
- |
2020 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
4.5 L |
- |
2020 |
Glenmark Pharmaceuticals Ltd.
|
Independent Director |
4 L |
-63.6 % |
2019 |
Glenmark Pharmaceuticals Ltd.
|
Independent Director |
11 L |
-31.2 % |
2018 |
Glenmark Pharmaceuticals Ltd.
|
Independent Director |
16 L |
45.5 % |
2018 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
3.7 L |
15.6 % |
2017 |
Glenmark Pharmaceuticals Ltd.
|
Director |
11 L |
-1.8 % |
2017 |
Hathway Cable & Datacom Ltd.
|
Chairman & Independent Directo |
3.2 L |
14.3 % |
2016 |
Glenmark Pharmaceuticals Ltd.
|
Independent Director |
11.2 L |
- |
2016 |
Hathway Cable & Datacom Ltd.
|
Independent Director |
2.8 L |
- |